

Market wrap Feb. 11, 2020

Indian equities rally significantly; stock specific action witnessed..

Domestic bourses bounced back as investors comforted from the decline in the rate of newly reported cases of Coronavirus in China. Broad-based buying across sectors lifted the benchmark S&P BSE Sensex to 41,216 level, up 237 points or 0.58 per cent. NTPC, Maruti Suzuki, Power Grid, and IndusInd Bank, up in the range of 1.6 and 3 per cent, settled the day as the top gainers on the 30-share index. On the flipside, Nestle India, Bharti Airtel, M&M, and TCS were the top laggards.

On the NSE, the broader 50-share index managed to hold the 12,100-mark and closed at 12,108 level, up 76 points or 0.63 per cent.

In the intra-day deals, the Sensex and Nifty50 hit a high of 41,444.34 and 12,172.30 level, respectively.

On the sectoral front, only Nifty FMCG index slipped into the red at close, down 0.3 per cent. On the upside, Nifty Bank, Pharma, Metal, and Private Bank indices added 0.8 per cent each.

The broader market counters, however, underperformed today. The S&P BSE mid-cap index closed 0.35 per cent higher at 15,836 level, meanwhile the S&P BSE small-cap index slipped 0.19 per cent to close at 14,748 level.

Crude oil

In commodities, oil prices rose around 1 per cent on Tuesday. Brent crude rose 53 cents, nearly 1 per cent, to \$53.80 a barrel, retreating from an intraday high of \$54.16. US West Texas Intermediate was up 46 cents, about 1 per cent, at \$50.18 a barrel.

Sectors and stocks

Shares of Wockhardt extended their gains to third straight day, surging 10 per cent to hit a 7-month high of Rs. 399, on the BSE on Tuesday on back of heavy volumes. The stock was trading at its highest level since June 27, 2019. In the past one month, the stock of the pharmaceutical company has zoomed 63 per cent, as compared to a 0.58 per cent rise in the S&P BSE Sensex. On January 16, 2020, the Mumbai-based company became the first Indian pharmaceutical company to get the drug regulator's nod for two novel antibiotics, which it plans to launch in the next few months in the domestic market. "The Drug Controller General of India (DCGI) has approved Emrok (injectable) and Emrok O (oral), used for acute bacterial skin and skin structure infections, including diabetic foot infections. The approval is based on a phase 3 clinical study involving 500 patients in 40 centres across India. The new drug will target superbugs, which have become resistant to other molecules," it said in a statement. Meanwhile, for the first time in the past 3 years, Wockhardt bounced back to net profit of Rs 9 crore in the December 2019 quarter (Q3FY20), owing to marked improvement in operational performance and cost rationalisation. It had posted a net loss of Rs 82 crore in the previous quarter, and of Rs. 121 crore in the year-ago quarter. EBITDA for the quarter showed a substantial improvement from Rs. 19 crore in Q3FY19 to Rs. 109 crore in Q3FY20. Ebitda margin expanded to 12.5 per cent from 1.9 per cent in year ago quarter. However, sales during the quarter under review were at Rs. 869 crore, lower by 17 per cent relative to corresponding quarter of the previous year.

Shares of Sheela Foam surged 12 per cent to Rs. 1,770, also its 52-week high, on the BSE on Tuesday after the company's consolidated profit before tax (PBT) jumped 52 per cent year on year (YoY) to Rs. 85.85 crore in the December 2019 quarter (Q3FY20). It had a PBT of Rs. 56.50 crore in the year ago quarter. The stock



surpassed its previous 52-week high of Rs. 1,639 touched on February 7, 2020. Besides, it is 4.5 percent away from its all-time high of Rs. 1,850 touched on November 29, 2017. In the past one month, the stock has outperformed the market by zooming 31 per cent, as against a 0.48 per cent decline in the S&P BSE Sensex. Sheela Foam's consolidated net profit grew 67 per cent to Rs. 65 crore from Rs. 39 crore in the corresponding quarter of previous fiscal. Consolidated revenue, too, rose 15.6 per cent at Rs. 658 crore relative to Rs. 569 crore logged in the previous year quarter. EBITDA margins improved to 14.3 per cent from 10.7 per cent.

Shares of GMM Pfaudler rallied 13 per cent to hit an all-time high of Rs. 3,285 on the BSE on Tuesday on the back of heavy volumes. The stock surpassed its previous high of Rs. 3,048, touched on February 5, 2020. GMM Pfaudler is a leading supplier of process equipment to the pharmaceutical and chemical industry segments. The company reported a strong 74 per cent year-on-year (YoY) jump in its consolidated net profit at Rs 21.1 crore for the quarter ended December 2019 (Q3FY20). It had a profit of Rs. 12.1 crore in the year-ago quarter. Operating revenue increased by 19 per cent to Rs. 156 crore from Rs. 131 crore in the corresponding quarter of previous fiscal. EBITDA improved significantly by 46 per cent YoY at Rs. 30.4 crore, while margins expanded 400 basis points to 20 per cent versus 16 per cent in Q3 of last year. Higher realisations, lower commodity costs, greater operating leverage and more export orders in Q3FY20 expanded the Ebitda margin. The management said the order book continues to remain healthy on the back of strong demand from the chemical and pharmaceutical sectors. The company will selectively add capacity looking at the robust demand environment. The Company has also laid out a five-year plan with an aim to take the Company to next level of sustainable growth, it said.

Global Markets

European shares rose to a record high early Tuesday as a slowdown in the rate of new infections in the coronavirus outbreak provided some relief, although markets still worried over the wider global economic impact. The pan-European STOXX 600 index rose as much as 0.7 per cent to a record high of 427.46.

In Asia, MSCI's broadest index of Asia-Pacific shares outside Japan rose 0.9 per cent, with Shanghai blue chips ahead by 0.8 per cent.

Japan's Nikkei was closed for a holiday, although Nikkei futures traded 0.8 per cent firmer. Futures for the EUROSTOXX 50 rose 0.7 per cent and the FTSE 0.5 per cent.



Disclaimer

Ajcon Global Services Ltd. is a fully integrated investment banking, merchant banking, corporate advisory, stock broking, commodity and currency broking. Ajcon Global Services Ltd. research analysts responsible for the preparation of the research report may interact with trading desk personnel, sales personnel and other parties for gathering, applying and interpreting information.

Ajcon Global Services Ltd. is a SEBI registered Research Analyst entity bearing registration Number INH000001170 under SEBI (Research Analysts) Regulations, 2014.

Individuals employed as research analyst by Ajcon Global Services Ltd. or their associates are not allowed to deal or trade in securities that the research analyst recommends within thirty days before and within five days after the publication of a research report as prescribed under SEBI Research Analyst Regulations.

Subject to the restrictions mentioned in above para, We and our affliates, officers, directors, employees and their relative may: (a) from time to time, have long or short positions acting as a principal in, and buy or sell the securities or derivatives thereof, of Company mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage.

Ajcon Global Services Ltd. or its associates may have commercial transactions with the Company mentioned in the research report with respect to advisory services.

The information and opinions in this report have been prepared by Ajcon Global Services Ltd. and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of Ajcon Global Services Ltd. While we would endeavour to update the information herein on a reasonable basis, Ajcon Global Services Ltd. is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent Ajcon Global Services Ltd. from doing so. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. Ajcon Global Services Ltd. will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. Ajcon Global Services Ltd. accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Ajcon Global Services Ltd. or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

Ajcon Global Services Ltd. encourages independence in research report preparation and strives to minimize conflict in preparation of research report. Ajcon Global Services Ltd. or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither Ajcon Global Services Ltd. nor Research Analysts have any material conflict of interest at the time of publication of this report. It is confirmed that Akash Jain – MBA (Financial Markets) or any other Research Analysts of this report has not received any compensation from the company mentioned in the report in the preceding twelve months.



Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

Ajcon Global Services Ltd. or its subsidiaries collectively or Directors including their relatives, Research Analysts, do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

It is confirmed that Akash Jain – MBA (Financial Markets) research analyst or any other Research Analysts of Ajcon Global do not serve as an officer, director or employee of the companies mentioned in the report.

Ajcon Global Services Ltd. may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor Ajcon Global Services Ltd. have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on Ajcon Global Services Ltd. by any Regulatory Authority impacting Equity Research Analysis activities.

Analyst Certification

I, Akash Jain MBA (Financial Markets), research analyst, author and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. I also certify that no part of compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view (s) in this report.

For research related queries contact:

Mr. Akash Jain - Vice President (Research) at, 022-67160431 (D)

CIN: L74140MH1986PLC041941

SEBI registration Number: INH000001170 as per SEBI (Research Analysts) Regulations, 2014.

Website: www.ajcononline.com

Registered and Corporate office

408 - $(4^{th}$ Floor), Express Zone, "A" Wing, Cello – Sonal Realty, Near Oberoi Mall and Patel's, Western Express Highway, Goregaon (East), Mumbai – 400063. Tel: 91-22-67160400, Fax: 022-28722062